Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: A randomized clinical trial

Ophthalmologica

Volumn 227, Issue 2, 2012, Pages 100-106

  Lim, Ji Won ^a   Lee, Hyo Kyoung ^a   Shin, Min Cheol ^a  

^a Hallym University   (South Korea)

Author keywords

Bevacizumab; Diabetic macular edema; Triamcinolone

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN A1C; TRIAMCINOLONE;

ADULT; ARTICLE; CENTRAL MACULAR THICKNESS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84856457338     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000331935     Document Type: Article

References (34)

1. Klein R, Klein B, Moss S, Cruickshanks K: The Wisconsin Epidemiologic Study of Diabetic Retinopathy XV: the long term incidence. Ophthalmology 1995;102:7-16.
2. Gottfredsdottir MS, Stefansson E, Jonasson F, Gislason I: Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 1993;115:64-67.
3. Early Treatment Diabetic Retinopathy Study Research group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report No 1. Arch Ophthalmol 1985;103:1796-1806.
4. Early Treatment Diabetic Retinopathy Study Research group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study report No 2. Ophthalmology 1987;94:761-774.
5. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A: Intravitreal triamcinolone acetonide for diabetic macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004;111:218-225.
6. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA: Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci 2005;46:3845-3849.
7. Jonas JB, Kreissig I, Sofker A, Degenring RF: Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
8. Yilmaz T, Weaver C-grave, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D, Lavaque AJ, Larson RJ: Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. Ophthalmology 2009;116:902-911.
9. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A: Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
10. Pan-American Collaborative Retina Study Group: Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the 6-month follow-up. Ophthalmology 2007;114:743-750.
11. Soheilian M, Ramezani A, Obudi A, Bijanzadeh B, Salehipour M, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Peyman GA: Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009;116:1142-1150.
12. Diabetic Retinopathy Clinical Research Network: A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007;114:1860-1867.
13. Nicholson BP, Schachat AP: A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:915-930.
14. Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M, Soheilian M, Keshavarzi G, Mohebbi MR: Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema: a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol 2008;246:483-489.
15. Wang YS, Li X, Wang HY, Zhang ZF, Li MH, Su XN: Intravitreal bevacizumab combined with/without triamcinolone acetonide in single injection for treatment of diabetic macular edema. Chin Med J 2011;124:352-358.
16. Synek S, Vojnikoviæ B: Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular oedema. Coll Antropol 2010;34(suppl 2):99-103.
17. Shimura M, Nakazawa T, Yasuda K, Shiono T, Iida T, Sakamoto T, Nishida K: Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol 2008;145:854-861.
18. Paccola L, Costa RA, Folgosa MS, Barbosa JC, Scott IU, Jorge R: Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008;92:76-80.
19. Kreutzer TC, Al Saeidi R, Kook D, Wolf A, Ulbig MW, Neubauer AS, Haritoglou C: Comparison of intravitreal bevacizumab versus triamcinolone for the treatment of diffuse diabetic macular edema. Ophthalmologica 2010;224:258-264.
20. Faghihi H, Roohipoor R, Mohammadi SF, Hojat-Jalali K, Mirshahi A, Lashay A, Piri N, Faghihi SH: Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008;18:941-948.
21. Age-Related Eye Disease Study Research Group: The Age-Related Eye Disease Study (ARE-graveS) system for classifying cataracts from photographs: ARE-graveS report No 4. Am J Ophthalmol 2001;131:167-175.
22. Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, Azarmina M, Moradian S, Tabatabaei H, Peyman GA: Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-1195.
23. Rensch F, Spandau UH, Wickenhäuser A, Jonas JB: Diffuse diabetic macular oedema treated with intravitreal bevacizumab or triamcinolone acetonide. Acta Ophthalmol 2010;88:e36-e37.
24. Qaum T, Xu Q, Joussen AM, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos G-grave, Adamis AP: VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001;42:2408-2413.
25. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y: Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005;46:1062-1068.
26. Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
27. Witmer A, Vrensen G, van Noorden C, Schlingemann R: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
28. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC: Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 2008;57:1026-1033.
29. Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, Gaudric A, Massin P: Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 2006;142:794-799.
30. Diabetic Retinopathy Clinical Research Network: A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-1449.
31. Chuang LH, Yeung L, Wang NK, Chen HS, Ku WC, Lai CC: Secondary ocular hypertension after intravitreal injection with 2 mg or 4 mg of triamcinolone in retinal vein occlusion. J Ocul Pharmacol Ther 2010;26:325-328.
32. Roth DB, Verma V, Realini T, Prenner JL, Feuer WJ, Fechtner R-grave: Long-term incidence and timing of intraocular hypertension after intravitreal triamcinolone acetonide injection. Ophthalmology 2009;116:455-460.
33. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M: Intravitreal triamcinolone for refractory diabetic macular edema: twoyear results of a double-masked, placebocontrolled, randomized clinical trial. Ophthalmology 2006;113:1533-1538.
34. Funk M, Schmidinger G, Maar N, Bolz M, Benesch T, Zlabinger GJ, Schmidt-Erfurth UM: Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 2010;30:1412-1419.